Suggested Remit: To appraise the clinical and cost effectiveness of lorlatinib within its marketing authorisation for treating ALK-positive advanced non-small-cell lung cancer.
 
Status In progress
Process STA 2018
ID number 1338

Project Team

Project lead Kate Moore

Email enquiries

Evidence Review Group / Assessment Group Health Economics Research Unit and Health Services Research Unit, University of Aberdeen

Consultees

Companies sponsors Pfizer (lorlatinib)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups ALK Positive UK
Professional groups Association of Cancer Physicians
  British Thoracic Society
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Comparator companies Merck Sharp & Dohme (pembrolizumab)
  Roche Products (atezolizumab, bevacizumab)
General commentators All Wales Therapeutic and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
28 January 2020 - 18 February 2020 Appraisal consultation
07 January 2020 Committee meeting
02 May 2019 Invitation to participate
19 December 2018 Following the referral of lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer to NICE by the Department for Health and Social Care. Following on from advice received from the company, the timelines are currently to be confirmed. Therefore, we are suspending this appraisal. We will provide a further update and timelines in due course.
25 October 2018 The company who produces lorlatinib, Pfizer, has requested more time to allow additional data to be included in the submission. As a consequence, the first committee meeting discussion has been moved to 16 April 2019.
06 September 2018 Invitation to participate
28 June 2018 - 26 July 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
05 December 2017 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance